Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or... see more

Recent & Breaking News (NDAQ:KROS)

Lost Money on Keros Therapeutics, Inc.(KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Accesswire 9 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

Accesswire 9 days ago

Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS

Accesswire 9 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Connect

Accesswire 9 days ago

Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS

Accesswire 10 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS  

Accesswire 10 days ago

Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud

Accesswire 10 days ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Accesswire 10 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation

Accesswire 11 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS  

Accesswire 13 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation

Accesswire 13 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS  

Accesswire December 12, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out

Accesswire December 12, 2024

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

GlobeNewswire December 12, 2024

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 9, 2024

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

GlobeNewswire December 3, 2024

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

GlobeNewswire November 26, 2024

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

GlobeNewswire November 6, 2024

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

GlobeNewswire November 6, 2024

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 5, 2024